Leqvio (inclisiran) Q2 2026 revenue reaches $480M, up 59% year-over-year, with peak sales target of $4-5B

Novartis/Leqvio

Novartis reported strong Q2 2026 financial results for Leqvio, with revenue reaching $480 million, representing 59% year-over-year growth. The company guided peak sales of $4-5 billion, reflecting growing adoption of the twice-yearly siRNA cholesterol drug across approved patient populations.

• Leqvio revenue reached $480M in Q2 2026, up 59% from Q2 2025.
• Represents one of the fastest-growing pharma franchises in lipid management.
• Peak sales guidance of $4-5B reflects Novartis' confidence in market penetration.
• Growth driven by expanded label approvals and increasing patient awareness.